ST目药
(600671)
| 流通市值：11.59亿 | | | 总市值：11.59亿 |
| 流通股本：1.22亿 | | | 总股本：1.22亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 124,680,446.71 | 59,548,398.28 | 27,735,233.63 | 121,778,535.85 |
| 营业收入 | 124,680,446.71 | 59,548,398.28 | 27,735,233.63 | 121,778,535.85 |
| 二、营业总成本 | 129,724,584.88 | 84,573,860.37 | 38,900,790.52 | 151,535,713.26 |
| 营业成本 | 71,362,825.86 | 43,458,675.67 | 19,298,631.81 | 95,246,382.08 |
| 税金及附加 | 973,931.35 | 404,123.5 | 39,222.03 | 1,049,681.49 |
| 销售费用 | 4,464,595.57 | 4,554,216.37 | 2,089,203.84 | 2,466,301.22 |
| 管理费用 | 47,406,264.16 | 31,789,446.65 | 16,044,127.35 | 45,160,085.53 |
| 研发费用 | 106,796.12 | 106,796.12 | - | 482,216.65 |
| 财务费用 | 5,410,171.82 | 4,260,602.06 | 1,429,605.49 | 7,131,046.29 |
| 其中:利息费用 | 5,298,591.54 | 4,223,004.23 | 1,553,175.91 | 7,185,061.94 |
| 其中:利息收入 | 351,201.62 | 262,490.84 | 146,159.24 | 112,768.9 |
| 加:投资收益 | 28,842.06 | 28,842.06 | - | -525,926.17 |
| 资产处置收益 | -137,260.06 | - | - | 333,474.11 |
| 资产减值损失(新) | 115,516.33 | 115,516.33 | 123,362.23 | -8,872,375.28 |
| 信用减值损失(新) | -2,643,053.74 | 170,329.04 | 42,680.13 | 511,703.19 |
| 其他收益 | 374,534.39 | 264,259.5 | 83,327.36 | 740,864.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -7,305,559.19 | -24,446,515.16 | -10,916,187.17 | -37,569,436.7 |
| 加:营业外收入 | 4,931,772.57 | 3,940,042.17 | 1,059,000.54 | 6,626,323.3 |
| 减:营业外支出 | 1,254,008.67 | 875,550.78 | 215,484.97 | 5,367,059.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,627,795.29 | -21,382,023.77 | -10,072,671.6 | -36,310,173.34 |
| 减:所得税费用 | 133,270.88 | -2,495,443.63 | 25,788.25 | 2,985,357.28 |
| 六、净利润 | -3,761,066.17 | -18,886,580.14 | -10,098,459.85 | -39,295,530.62 |
| 持续经营净利润 | -3,761,066.17 | -18,886,580.14 | -10,098,459.85 | -39,008,547.64 |
| 终止经营净利润 | - | - | - | -286,982.98 |
| 归属于母公司股东的净利润 | -3,695,546.06 | -18,500,728.95 | -9,722,783.48 | -38,275,148 |
| 少数股东损益 | -65,520.11 | -385,851.19 | -375,676.37 | -1,020,382.62 |
| (一)基本每股收益 | -0.03 | -0.15 | -0.08 | -0.31 |
| (二)稀释每股收益 | -0.03 | -0.15 | -0.08 | -0.31 |
| 九、综合收益总额 | -3,761,066.17 | -18,886,580.14 | -10,098,459.85 | -39,295,530.62 |
| 归属于母公司股东的综合收益总额 | -3,695,546.06 | -18,500,728.95 | -9,722,783.48 | -38,275,148 |
| 归属于少数股东的综合收益总额 | -65,520.11 | -385,851.19 | -375,676.37 | -1,020,382.62 |
| 公告日期 | 2024-10-30 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |